↓ Skip to main content

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study

Overview of attention for article published in Arthritis Research & Therapy, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
66 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study
Published in
Arthritis Research & Therapy, January 2013
DOI 10.1186/ar4315
Pubmed ID
Authors

Shintaro Hirata, Kazuyoshi Saito, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Shigeru Iwata, Masao Nawata, Norifumi Sawamukai, Kazuhisa Nakano, Kunihiro Yamaoka, Yoshiya Tanaka

Abstract

Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to investigate whether disease activity score 28 (DAS28)- erythrocyte sedimentation rate (ESR) remission was preserved after discontinuation of ADA in patients with RA.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 65 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 14%
Student > Master 9 14%
Researcher 9 14%
Other 8 12%
Student > Doctoral Student 5 8%
Other 16 24%
Unknown 10 15%
Readers by discipline Count As %
Medicine and Dentistry 40 61%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Agricultural and Biological Sciences 3 5%
Biochemistry, Genetics and Molecular Biology 2 3%
Computer Science 1 2%
Other 3 5%
Unknown 12 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2013.
All research outputs
#2,436,989
of 11,340,339 outputs
Outputs from Arthritis Research & Therapy
#446
of 1,556 outputs
Outputs of similar age
#28,858
of 147,787 outputs
Outputs of similar age from Arthritis Research & Therapy
#11
of 61 outputs
Altmetric has tracked 11,340,339 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,556 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 147,787 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.